Loading…
Effect of Alendronate on Periodontal Disease in Postmenopausal Women: A Randomized Placebo‐Controlled Trial
Background: We investigated the effect of oral alendronate (ALN) treatment on radiological and clinical measurements of periodontal disease in postmenopausal women without hormone replacement therapy. Methods: We evaluated the effect of 6 months of ALN treatment in 40 postmenopausal women, 55 to 65...
Saved in:
| Published in: | Journal of periodontology (1970) 2004-12, Vol.75 (12), p.1579-1585 |
|---|---|
| Main Authors: | , , , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c3499-def389214f52eb426763f96f1d3fed1419c934caf1d9e9981ac489668f3699e13 |
|---|---|
| cites | |
| container_end_page | 1585 |
| container_issue | 12 |
| container_start_page | 1579 |
| container_title | Journal of periodontology (1970) |
| container_volume | 75 |
| creator | Rocha, Miriam L. Malacara, Juan M. Sánchez‐Marin, Francisco J. Torre, Carlos J. Vazquez Fajardo, Martha E. |
| description | Background: We investigated the effect of oral alendronate (ALN) treatment on radiological and clinical measurements of periodontal disease in postmenopausal women without hormone replacement therapy.
Methods: We evaluated the effect of 6 months of ALN treatment in 40 postmenopausal women, 55 to 65 years old with established periodontal disease, in a controlled, double‐masked, prospective study. Volunteers were paired by age and randomized to receive ALN (10 mg/day) or placebo for the study period. Periodontal mechanical treatment was carried out in both groups. At baseline and after treatment, clinical evaluation, hormone blood levels, distance from the crestal alveolar bone (CAB) to the cemento‐enamel junction (CEJ), calcaneus bone mineral density (BMD), hormone levels, serum N‐telopeptide (NTx), and bone‐specific alkaline phosphatase (BSAP) were assessed.
Results: Periodontal disease conditions improved in both groups, but greater improvement in probing depth (–0.8 ± 0.3 mm versus –0.4 ± 0.4 mm, P = 0.02) and gingival bleeding (–0.3% ± 0.13% versus –0.2% ± 0.06%, P = 0.006) was found in the ALN treated group. Calcaneus BMD increased in the ALN treated group (68 ± 47 mm3 versus –26 ± 81 mm3, P = 0.0006). CAB‐CEJ distance diminished in the ALN group (–0.4 ± 0.40 mm versus 0.60 ± 0.53 mm, P = 0.00008). Marginal reduction in both NTx and BSAP levels was found in the ALN group (–9.4 ± 6.6 nmol versus –4.3 ± 4.7 nmol bone collagen equivalents, P = 0.08, and –7.7 ± 8.4 versus –1.5 ± 5.0 U/l, P = 0.1, respectively). Hormone levels were unchanged after treatment. Similar improvement of calcaneus BMD and CAB‐CEJ distance with ALN treatment was found in obese and non‐obese women.
Conclusion: ALN treatment improved periodontal disease and bone turnover in postmenopausal women. J Periodontol 2004; 75:1579‐1585. |
| doi_str_mv | 10.1902/jop.2004.75.12.1579 |
| format | article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67256463</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>67256463</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3499-def389214f52eb426763f96f1d3fed1419c934caf1d9e9981ac489668f3699e13</originalsourceid><addsrcrecordid>eNqNkM1KxDAUhYMoOv48gSBZuWvNX9PG3TCOfwgOorgMmfYGKmkzJh1EVz6Cz-iTmHEG3Lq63HPPOVw-hI4pyaki7OzFL3JGiMjLIqcsp0WpttCIKsEzLkuyjUaEMJZxodge2o_xJa1UcLKL9pKXs6ooR6ibWgv1gL3FYwd9E3xvBsC-xzMIrW98PxiHL9oIJgJuk-zj0EHvF2YZ0-XZp-Ucj_GD6RvftR_Q4JkzNcz99-fXJMWDdy6Jj6E17hDtWOMiHG3mAXq6nD5OrrO7-6ubyfguq9O3KmvA8kqlZ23BYC6YLCW3SlracAsNFVTViovaJEGBUhU1taiUlJXlUimg_ACdrnsXwb8uIQ66a2MNzpke_DJqWbJCCsmTka-NdfAxBrB6EdrOhHdNiV5R1omyXlHWZaEp0yvKKXWyqV_OO2j-MhusyaDWhrfWwft_OvXtbPrwW_4DFdaMCw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>67256463</pqid></control><display><type>article</type><title>Effect of Alendronate on Periodontal Disease in Postmenopausal Women: A Randomized Placebo‐Controlled Trial</title><source>Wiley</source><creator>Rocha, Miriam L. ; Malacara, Juan M. ; Sánchez‐Marin, Francisco J. ; Torre, Carlos J. Vazquez ; Fajardo, Martha E.</creator><creatorcontrib>Rocha, Miriam L. ; Malacara, Juan M. ; Sánchez‐Marin, Francisco J. ; Torre, Carlos J. Vazquez ; Fajardo, Martha E.</creatorcontrib><description>Background: We investigated the effect of oral alendronate (ALN) treatment on radiological and clinical measurements of periodontal disease in postmenopausal women without hormone replacement therapy.
Methods: We evaluated the effect of 6 months of ALN treatment in 40 postmenopausal women, 55 to 65 years old with established periodontal disease, in a controlled, double‐masked, prospective study. Volunteers were paired by age and randomized to receive ALN (10 mg/day) or placebo for the study period. Periodontal mechanical treatment was carried out in both groups. At baseline and after treatment, clinical evaluation, hormone blood levels, distance from the crestal alveolar bone (CAB) to the cemento‐enamel junction (CEJ), calcaneus bone mineral density (BMD), hormone levels, serum N‐telopeptide (NTx), and bone‐specific alkaline phosphatase (BSAP) were assessed.
Results: Periodontal disease conditions improved in both groups, but greater improvement in probing depth (–0.8 ± 0.3 mm versus –0.4 ± 0.4 mm, P = 0.02) and gingival bleeding (–0.3% ± 0.13% versus –0.2% ± 0.06%, P = 0.006) was found in the ALN treated group. Calcaneus BMD increased in the ALN treated group (68 ± 47 mm3 versus –26 ± 81 mm3, P = 0.0006). CAB‐CEJ distance diminished in the ALN group (–0.4 ± 0.40 mm versus 0.60 ± 0.53 mm, P = 0.00008). Marginal reduction in both NTx and BSAP levels was found in the ALN group (–9.4 ± 6.6 nmol versus –4.3 ± 4.7 nmol bone collagen equivalents, P = 0.08, and –7.7 ± 8.4 versus –1.5 ± 5.0 U/l, P = 0.1, respectively). Hormone levels were unchanged after treatment. Similar improvement of calcaneus BMD and CAB‐CEJ distance with ALN treatment was found in obese and non‐obese women.
Conclusion: ALN treatment improved periodontal disease and bone turnover in postmenopausal women. J Periodontol 2004; 75:1579‐1585.</description><identifier>ISSN: 0022-3492</identifier><identifier>EISSN: 1943-3670</identifier><identifier>DOI: 10.1902/jop.2004.75.12.1579</identifier><identifier>PMID: 15732857</identifier><language>eng</language><publisher>737 N. Michigan Avenue, Suite 800, Chicago, IL 60611‐2690, USA: American Academy of Periodontology</publisher><subject>Administration, Oral ; Aged ; Alendronate - administration & dosage ; Alendronate/therapeutic use ; Alveolar Bone Loss - diagnostic imaging ; Alveolar Bone Loss - prevention & control ; alveolar bone loss/prevention and control ; bisphosphonates/therapeutic use ; Bone Density - drug effects ; clinical trials, controlled ; Dentistry ; Double-Blind Method ; double‐masked method ; Female ; follow‐up studies ; Gingival Recession - prevention & control ; Humans ; Middle Aged ; Obesity - physiopathology ; Periodontal Diseases - drug therapy ; Periodontal Index ; Postmenopause - drug effects ; postmenopause/complications ; Prospective Studies ; Radiography ; Tooth Mobility - prevention & control</subject><ispartof>Journal of periodontology (1970), 2004-12, Vol.75 (12), p.1579-1585</ispartof><rights>2004 American Academy of Periodontology</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c3499-def389214f52eb426763f96f1d3fed1419c934caf1d9e9981ac489668f3699e13</citedby></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1902%2Fjop.2004.75.12.1579$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1902%2Fjop.2004.75.12.1579$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>315,786,790,27957,27958,50923,51032</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15732857$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Rocha, Miriam L.</creatorcontrib><creatorcontrib>Malacara, Juan M.</creatorcontrib><creatorcontrib>Sánchez‐Marin, Francisco J.</creatorcontrib><creatorcontrib>Torre, Carlos J. Vazquez</creatorcontrib><creatorcontrib>Fajardo, Martha E.</creatorcontrib><title>Effect of Alendronate on Periodontal Disease in Postmenopausal Women: A Randomized Placebo‐Controlled Trial</title><title>Journal of periodontology (1970)</title><addtitle>J Periodontol</addtitle><description>Background: We investigated the effect of oral alendronate (ALN) treatment on radiological and clinical measurements of periodontal disease in postmenopausal women without hormone replacement therapy.
Methods: We evaluated the effect of 6 months of ALN treatment in 40 postmenopausal women, 55 to 65 years old with established periodontal disease, in a controlled, double‐masked, prospective study. Volunteers were paired by age and randomized to receive ALN (10 mg/day) or placebo for the study period. Periodontal mechanical treatment was carried out in both groups. At baseline and after treatment, clinical evaluation, hormone blood levels, distance from the crestal alveolar bone (CAB) to the cemento‐enamel junction (CEJ), calcaneus bone mineral density (BMD), hormone levels, serum N‐telopeptide (NTx), and bone‐specific alkaline phosphatase (BSAP) were assessed.
Results: Periodontal disease conditions improved in both groups, but greater improvement in probing depth (–0.8 ± 0.3 mm versus –0.4 ± 0.4 mm, P = 0.02) and gingival bleeding (–0.3% ± 0.13% versus –0.2% ± 0.06%, P = 0.006) was found in the ALN treated group. Calcaneus BMD increased in the ALN treated group (68 ± 47 mm3 versus –26 ± 81 mm3, P = 0.0006). CAB‐CEJ distance diminished in the ALN group (–0.4 ± 0.40 mm versus 0.60 ± 0.53 mm, P = 0.00008). Marginal reduction in both NTx and BSAP levels was found in the ALN group (–9.4 ± 6.6 nmol versus –4.3 ± 4.7 nmol bone collagen equivalents, P = 0.08, and –7.7 ± 8.4 versus –1.5 ± 5.0 U/l, P = 0.1, respectively). Hormone levels were unchanged after treatment. Similar improvement of calcaneus BMD and CAB‐CEJ distance with ALN treatment was found in obese and non‐obese women.
Conclusion: ALN treatment improved periodontal disease and bone turnover in postmenopausal women. J Periodontol 2004; 75:1579‐1585.</description><subject>Administration, Oral</subject><subject>Aged</subject><subject>Alendronate - administration & dosage</subject><subject>Alendronate/therapeutic use</subject><subject>Alveolar Bone Loss - diagnostic imaging</subject><subject>Alveolar Bone Loss - prevention & control</subject><subject>alveolar bone loss/prevention and control</subject><subject>bisphosphonates/therapeutic use</subject><subject>Bone Density - drug effects</subject><subject>clinical trials, controlled</subject><subject>Dentistry</subject><subject>Double-Blind Method</subject><subject>double‐masked method</subject><subject>Female</subject><subject>follow‐up studies</subject><subject>Gingival Recession - prevention & control</subject><subject>Humans</subject><subject>Middle Aged</subject><subject>Obesity - physiopathology</subject><subject>Periodontal Diseases - drug therapy</subject><subject>Periodontal Index</subject><subject>Postmenopause - drug effects</subject><subject>postmenopause/complications</subject><subject>Prospective Studies</subject><subject>Radiography</subject><subject>Tooth Mobility - prevention & control</subject><issn>0022-3492</issn><issn>1943-3670</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><recordid>eNqNkM1KxDAUhYMoOv48gSBZuWvNX9PG3TCOfwgOorgMmfYGKmkzJh1EVz6Cz-iTmHEG3Lq63HPPOVw-hI4pyaki7OzFL3JGiMjLIqcsp0WpttCIKsEzLkuyjUaEMJZxodge2o_xJa1UcLKL9pKXs6ooR6ibWgv1gL3FYwd9E3xvBsC-xzMIrW98PxiHL9oIJgJuk-zj0EHvF2YZ0-XZp-Ucj_GD6RvftR_Q4JkzNcz99-fXJMWDdy6Jj6E17hDtWOMiHG3mAXq6nD5OrrO7-6ubyfguq9O3KmvA8kqlZ23BYC6YLCW3SlracAsNFVTViovaJEGBUhU1taiUlJXlUimg_ACdrnsXwb8uIQ66a2MNzpke_DJqWbJCCsmTka-NdfAxBrB6EdrOhHdNiV5R1omyXlHWZaEp0yvKKXWyqV_OO2j-MhusyaDWhrfWwft_OvXtbPrwW_4DFdaMCw</recordid><startdate>200412</startdate><enddate>200412</enddate><creator>Rocha, Miriam L.</creator><creator>Malacara, Juan M.</creator><creator>Sánchez‐Marin, Francisco J.</creator><creator>Torre, Carlos J. Vazquez</creator><creator>Fajardo, Martha E.</creator><general>American Academy of Periodontology</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>200412</creationdate><title>Effect of Alendronate on Periodontal Disease in Postmenopausal Women: A Randomized Placebo‐Controlled Trial</title><author>Rocha, Miriam L. ; Malacara, Juan M. ; Sánchez‐Marin, Francisco J. ; Torre, Carlos J. Vazquez ; Fajardo, Martha E.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3499-def389214f52eb426763f96f1d3fed1419c934caf1d9e9981ac489668f3699e13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Administration, Oral</topic><topic>Aged</topic><topic>Alendronate - administration & dosage</topic><topic>Alendronate/therapeutic use</topic><topic>Alveolar Bone Loss - diagnostic imaging</topic><topic>Alveolar Bone Loss - prevention & control</topic><topic>alveolar bone loss/prevention and control</topic><topic>bisphosphonates/therapeutic use</topic><topic>Bone Density - drug effects</topic><topic>clinical trials, controlled</topic><topic>Dentistry</topic><topic>Double-Blind Method</topic><topic>double‐masked method</topic><topic>Female</topic><topic>follow‐up studies</topic><topic>Gingival Recession - prevention & control</topic><topic>Humans</topic><topic>Middle Aged</topic><topic>Obesity - physiopathology</topic><topic>Periodontal Diseases - drug therapy</topic><topic>Periodontal Index</topic><topic>Postmenopause - drug effects</topic><topic>postmenopause/complications</topic><topic>Prospective Studies</topic><topic>Radiography</topic><topic>Tooth Mobility - prevention & control</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rocha, Miriam L.</creatorcontrib><creatorcontrib>Malacara, Juan M.</creatorcontrib><creatorcontrib>Sánchez‐Marin, Francisco J.</creatorcontrib><creatorcontrib>Torre, Carlos J. Vazquez</creatorcontrib><creatorcontrib>Fajardo, Martha E.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Journal of periodontology (1970)</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rocha, Miriam L.</au><au>Malacara, Juan M.</au><au>Sánchez‐Marin, Francisco J.</au><au>Torre, Carlos J. Vazquez</au><au>Fajardo, Martha E.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Effect of Alendronate on Periodontal Disease in Postmenopausal Women: A Randomized Placebo‐Controlled Trial</atitle><jtitle>Journal of periodontology (1970)</jtitle><addtitle>J Periodontol</addtitle><date>2004-12</date><risdate>2004</risdate><volume>75</volume><issue>12</issue><spage>1579</spage><epage>1585</epage><pages>1579-1585</pages><issn>0022-3492</issn><eissn>1943-3670</eissn><notes>ObjectType-Article-2</notes><notes>SourceType-Scholarly Journals-1</notes><notes>ObjectType-Feature-1</notes><notes>ObjectType-News-3</notes><notes>content type line 23</notes><abstract>Background: We investigated the effect of oral alendronate (ALN) treatment on radiological and clinical measurements of periodontal disease in postmenopausal women without hormone replacement therapy.
Methods: We evaluated the effect of 6 months of ALN treatment in 40 postmenopausal women, 55 to 65 years old with established periodontal disease, in a controlled, double‐masked, prospective study. Volunteers were paired by age and randomized to receive ALN (10 mg/day) or placebo for the study period. Periodontal mechanical treatment was carried out in both groups. At baseline and after treatment, clinical evaluation, hormone blood levels, distance from the crestal alveolar bone (CAB) to the cemento‐enamel junction (CEJ), calcaneus bone mineral density (BMD), hormone levels, serum N‐telopeptide (NTx), and bone‐specific alkaline phosphatase (BSAP) were assessed.
Results: Periodontal disease conditions improved in both groups, but greater improvement in probing depth (–0.8 ± 0.3 mm versus –0.4 ± 0.4 mm, P = 0.02) and gingival bleeding (–0.3% ± 0.13% versus –0.2% ± 0.06%, P = 0.006) was found in the ALN treated group. Calcaneus BMD increased in the ALN treated group (68 ± 47 mm3 versus –26 ± 81 mm3, P = 0.0006). CAB‐CEJ distance diminished in the ALN group (–0.4 ± 0.40 mm versus 0.60 ± 0.53 mm, P = 0.00008). Marginal reduction in both NTx and BSAP levels was found in the ALN group (–9.4 ± 6.6 nmol versus –4.3 ± 4.7 nmol bone collagen equivalents, P = 0.08, and –7.7 ± 8.4 versus –1.5 ± 5.0 U/l, P = 0.1, respectively). Hormone levels were unchanged after treatment. Similar improvement of calcaneus BMD and CAB‐CEJ distance with ALN treatment was found in obese and non‐obese women.
Conclusion: ALN treatment improved periodontal disease and bone turnover in postmenopausal women. J Periodontol 2004; 75:1579‐1585.</abstract><cop>737 N. Michigan Avenue, Suite 800, Chicago, IL 60611‐2690, USA</cop><pub>American Academy of Periodontology</pub><pmid>15732857</pmid><doi>10.1902/jop.2004.75.12.1579</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0022-3492 |
| ispartof | Journal of periodontology (1970), 2004-12, Vol.75 (12), p.1579-1585 |
| issn | 0022-3492 1943-3670 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_67256463 |
| source | Wiley |
| subjects | Administration, Oral Aged Alendronate - administration & dosage Alendronate/therapeutic use Alveolar Bone Loss - diagnostic imaging Alveolar Bone Loss - prevention & control alveolar bone loss/prevention and control bisphosphonates/therapeutic use Bone Density - drug effects clinical trials, controlled Dentistry Double-Blind Method double‐masked method Female follow‐up studies Gingival Recession - prevention & control Humans Middle Aged Obesity - physiopathology Periodontal Diseases - drug therapy Periodontal Index Postmenopause - drug effects postmenopause/complications Prospective Studies Radiography Tooth Mobility - prevention & control |
| title | Effect of Alendronate on Periodontal Disease in Postmenopausal Women: A Randomized Placebo‐Controlled Trial |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-09-22T13%3A13%3A31IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Effect%20of%20Alendronate%20on%20Periodontal%20Disease%20in%20Postmenopausal%20Women:%20A%20Randomized%20Placebo%E2%80%90Controlled%20Trial&rft.jtitle=Journal%20of%20periodontology%20(1970)&rft.au=Rocha,%20Miriam%20L.&rft.date=2004-12&rft.volume=75&rft.issue=12&rft.spage=1579&rft.epage=1585&rft.pages=1579-1585&rft.issn=0022-3492&rft.eissn=1943-3670&rft_id=info:doi/10.1902/jop.2004.75.12.1579&rft_dat=%3Cproquest_cross%3E67256463%3C/proquest_cross%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c3499-def389214f52eb426763f96f1d3fed1419c934caf1d9e9981ac489668f3699e13%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=67256463&rft_id=info:pmid/15732857&rfr_iscdi=true |